{
    "id": 3909,
    "fullName": "PIK3CA T1025A",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA T1025A lies within the PI3K/PI4K kinase domain of the Pik3ca protein (UniProt.org). T1025A has not been biochemically characterized, but is predicted to confer a gain of function on the Pik3ca protein as demonstrated by increased transformation ability in two different cell lines (PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "T1025A",
    "createDate": "03/19/2015",
    "updateDate": "06/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 172227,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179234230A>G",
        "cDna": "c.3073A>G",
        "protein": "p.T1025A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Pictilisib (GDC-0941) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9252,
                "therapyName": "MRTX849 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Buparlisib (BKM120) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9251,
                "therapyName": "Buparlisib + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Vistusertib (AZD2014) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 8999,
                "therapyName": "MRTX849 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRTX849 and Afinitor (everolimus) synergistically inhibited growth of a lung cancer cell line harboring KRAS G12C and PIK3CA T1025A in culture (PMID: 31658955).",
            "molecularProfile": {
                "id": 34670,
                "profileName": "KRAS G12C PIK3CA T1025A"
            },
            "therapy": {
                "id": 9000,
                "therapyName": "Everolimus + MRTX849",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16927,
                    "pubMedId": 31658955,
                    "title": "The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31658955"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3719,
            "profileName": "PIK3CA T1025A",
            "profileTreatmentApproaches": [
                {
                    "id": 18074,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA T1025A"
                },
                {
                    "id": 18078,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA T1025A"
                },
                {
                    "id": 18073,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA T1025A"
                },
                {
                    "id": 18076,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA T1025A"
                },
                {
                    "id": 18077,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA T1025A"
                },
                {
                    "id": 18072,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA T1025A"
                },
                {
                    "id": 18071,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA T1025A"
                },
                {
                    "id": 18075,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA T1025A"
                }
            ]
        },
        {
            "id": 34670,
            "profileName": "KRAS G12C PIK3CA T1025A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 172228,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179234230A>G",
            "cDna": "c.3073A>G",
            "protein": "p.T1025A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 172227,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179234230A>G",
            "cDna": "c.3073A>G",
            "protein": "p.T1025A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 172226,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179234230A>G",
            "cDna": "c.3073A>G",
            "protein": "p.T1025A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}